1. Indications:

Tukanic (Tucatinib) 150 mg is indicated for the treatment of:

• HER2-positive breast cancer, either alone or in combination with other anti-cancer therapies, in patients who have received prior treatment with HER2-targeted agents.

2. Pharmacology:

Tukanic (Tucatinib) 150 mg exerts its pharmacological effects by selectively inhibiting the activity of the HER2 protein. By blocking HER2 signaling pathways, Tucatinib inhibits cancer cell proliferation and survival, leading to tumor regression and inhibition of cancer progression.

3. Dosage and Administration:

The recommended dosage of Tukanic (Tucatinib) 150 mg may vary depending on individual patient characteristics and treatment regimen. Typically, the prescribed dose is 150 mg taken orally twice daily, with or without food. Tucatinib is often used in combination with other anti-cancer therapies, such as trastuzumab and capecitabine.

4. Interaction:

Tukanic (Tucatinib) 150 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Tucatinib.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Tucatinib, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Tukanic (Tucatinib) 150 mg may include:

• Diarrhea
• Nausea
• Fatigue
• Vomiting
• Elevated liver enzymes
• Decreased appetite

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Tukanic (Tucatinib) 150 mg, patients should be aware of the following precautions:

• Hepatotoxicity, including liver function abnormalities, has been reported with Tucatinib. Liver function tests should be performed before starting treatment and periodically thereafter.
• Diarrhea is a common side effect of Tucatinib and may require dose modifications or supportive care measures.
• Tucatinib may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least one week after the last dose.

7. Overdose Effects:

In case of overdose with Tukanic (Tucatinib) 150 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Tucatinib overdose, and patients should seek immediate medical attention if overdose is suspected.